PharmaCyte Biotech, Inc. (PMCB)
0.4865
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
0.49
0.00 (0.00%)
After-Hours: 20:00
PharmaCyte Biotech Enterprise Value : -30.59M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | -30.59M |
| September 03, 2026 | -30.54M |
| September 02, 2026 | -30.65M |
| September 01, 2026 | -30.57M |
| August 31, 2026 | -30.44M |
| August 28, 2026 | -30.29M |
| August 27, 2026 | -30.01M |
| August 26, 2026 | -30.01M |
| August 25, 2026 | -30.02M |
| August 24, 2026 | -30.18M |
| August 21, 2026 | -30.09M |
| August 20, 2026 | -30.29M |
| August 19, 2026 | -30.10M |
| August 18, 2026 | -30.19M |
| August 17, 2026 | -29.99M |
| August 14, 2026 | -29.90M |
| August 13, 2026 | -29.91M |
| August 12, 2026 | -29.94M |
| August 11, 2026 | -29.91M |
| August 10, 2026 | -29.95M |
| August 07, 2026 | -29.48M |
| August 06, 2026 | -29.48M |
| August 05, 2026 | -29.48M |
| August 04, 2026 | -29.36M |
| August 03, 2026 | -29.63M |
| Date | Value |
|---|---|
| July 31, 2026 | -29.63M |
| July 30, 2026 | -29.37M |
| July 29, 2026 | -29.53M |
| July 28, 2026 | -29.48M |
| July 27, 2026 | -29.53M |
| July 24, 2026 | -29.37M |
| July 23, 2026 | -29.32M |
| July 22, 2026 | -29.27M |
| July 21, 2026 | -29.26M |
| July 20, 2026 | -29.12M |
| July 17, 2026 | -29.02M |
| July 16, 2026 | -28.73M |
| July 15, 2026 | -28.24M |
| July 14, 2026 | -28.42M |
| July 13, 2026 | -28.73M |
| July 10, 2026 | -28.34M |
| July 09, 2026 | -28.30M |
| July 08, 2026 | -28.19M |
| July 07, 2026 | -28.18M |
| July 06, 2026 | -27.98M |
| July 02, 2026 | -28.14M |
| July 01, 2026 | -27.86M |
| June 30, 2026 | -27.55M |
| June 29, 2026 | -27.97M |
| June 26, 2026 | -27.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 615.81M |
| Amgen, Inc. | 279.68B |
| Anika Therapeutics, Inc. | 265.34M |
| BioCryst Pharmaceuticals, Inc. | 3.026B |
| Imunon, Inc. | 8.353M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.393M |
| Total Expenses (Quarterly) | 4.393M |
| EPS Diluted (Quarterly) | -0.454 |
| Earnings Yield | -635.3% |
| Normalized Earnings Yield | -298.05 |